A meta-analysis GWAS of taxane-induced peripheral neuropathy in patients with breast cancer. This is an ASCO Meeting Abstract from the 2024 ASCO Annual Meeting I. This abstract does not include a full ...

Cancer cachexia is a multifactorial syndrome characterized by skeletal muscle loss leading to progressive functional impairment. Despite the ubiquity of cachexia in clinical practice, prevention, ...

Pfizer said its experimental drug for a common, life-threatening condition that causes cancer patients to lose their appetite and weight showed positive results in a midstage trial. Patients with the ...

Cachexia in older SCLC patients leads to inferior survival rates and increased treatment complications, such as dose reductions and incomplete chemotherapy courses. Patients with cachexia had ...

Pfizer researchers say they are developing a drug that might counteract a condition that leads to the death of cancer patients within a year of its diagnosis. Photo by Stephanie Lecocq/EPA-EFE Sept.

A new phase 2b/3 trial was approved to study of S-pindolol benzoate to treat cachexia, a wasting disease associated with cancer. The Food and Drug Administration (FDA) OKed phase 2b/3 trials to ...

Eating disorders are often thought of as body image disorders with symptoms of food restriction and purging. In most cases, the goal of these behaviors is to prevent weight gain. Not all eating ...

Sept. 14 (UPI) --A drug that could reduce the risk of death in cancer patients is showing good promise during its second phase of clinical tests, drugmaker Pfizer announced Saturday. The experimental ...